Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 14/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.49 |
| ▸ | TEC | P42680 | 1/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.49 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.49 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25130670 | 1.00 | KRAS (0.53) | KRASSOS1EGFRERBB2RIPK2 | |
| SCHEMBL25130570 | 0.87 | PDE4B (0.55) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL14489848 | 0.84 | ACHE (0.57) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL29111062 | 0.84 | KRAS (0.50) | KRASSOS1EGFRERBB2ACHE | |
| SCHEMBL25130494 | 0.83 | PIK3CD (0.56) | KRASSOS1EGFRERBB2EPHB4 | |
| SCHEMBL28427821 | 0.81 | MET (0.48) | KRASSOS1MET | |
| SCHEMBL30646048 | 0.81 | PDGFRA (0.50) | KRASSOS1MET | |
| SCHEMBL28428914 | 0.80 | PDGFRA (0.49) | KRASSOS1MET | |
| SCHEMBL28430853 | 0.79 | SRC (0.55) | KRASSOS1EGFRERBB2MET | |
| SCHEMBL14489794 | 0.79 | MAPT (0.48) | KRASSOS1EGFRERBB2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042857-A1 | SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure | HAIHE BIOPHARMA CO., LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4410790-A1 | SOS1 INHIBITORS HAVING PYRIDO SIX-MEMBERED RING STRUCTURE | Haihe Biopharma Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023051628-A1 | SOS1 INHIBITORS HAVING PYRIDO SIX-MEMBERED RING STRUCTURE | 上海海和药物研究开发股份有限公司 | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042857-A1 | SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure | SOS1, MEN1, BRCA1 | KRAS 138/4885SOS1 1/4885EGFR 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.